ARRAYJET, the Edinburgh-based bio-printing and microarray technology company, has announced the appointment of its new non-executive Chairman.
Dr Joe Keegan, a San Francisco-based biotechnology entrepreneur and one of the most respected leaders in the global life sciences industry, will replace Edinburgh-based serial entrepreneur and business strategist Alan Faichney, who is stepping down as Chairman after seven years in the role.
Dr. Keegan’s appointed as Chairman is a huge boost for Arrayjet and the wider Scottish life sciences community. Joe joined Arrayjet as a non-exec Director three years ago and has been pivotal in helping the company accelerate a bold global expansion strategy.
He has helped identify and open up new international channels for Arrayjet’s bio-printing technology products which are now installed in an increasing number of medical research establishments, pharmaceutical companies, and universities, across the continents.
His elevation to Chairman brings further commercial focus and offers strategic assistance to CEO Iain McWilliam and the rest of the Arrayjet board to further strengthen and build on the reputation and successes that Arrayjet has achieved in recent years.
Dr Keegan has more than 30 years’ experience in life science businesses. In addition to his role at Arrayjet, he holds a number of other chairmanships at Carterra Inc; a Utah-headquartered high-throughput antibody screening company, Halo Labs Inc., based in California USA and Cambridge UK life science business, Fluidic Analytics Ltd.
He also holds directorships at Bio-Techne Corporation (NASDAQ: TECH), a publicly held biotech company, Interpace Biosciences Inc (NASDAQ: IDXG), a publicly held clinical and pharma services company, and the UK synthetic biology company Nuclera Nucleics Ltd. Dr Keegan holds a B.A. in Chemistry from Boston University and a Ph.D. in Physical Chemistry from Stanford University.
Iain McWilliam, CEO of Arrayjet commented;
“Joe’s assistance as a non-executive director has been invaluable and elevating him to Chairman was a natural progression. He remains one of the most powerful names in the global life sciences industry and will be an indispensable guide for me and the rest of the Arrayjet team as we take the business forward.
Moreover, I would like to thank Alan for his advice, leadership and guidance over the past seven years. He is renowned across several technology sectors and his stewardship as non-exec Chairman helped transform Arrayjet into one of the leading life sciences businesses in the country.”
Commenting on his appointment as Non-Executive Chairman at Arrayjet, Dr Keegan said,
“Arrayjet has exceptional global market potential, employs first-class people, and its research and development pipeline reaffirms why I remain genuinely excited about helping to build the business to the next level. We are positioned to generate significant growth in the years ahead.”